A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients

Citation

• Felip, E., Ranson, M., Cedres, S., Dean, E., De Droogh, E., Brewster, M., . . . Galdermans, D. (2008). A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients. Journal of Clinical Oncology, 26(15_suppl), 19134. doi:10.1200/jco.2008.26.15_suppl.19134

Digital Object Identifier (doi)

• 10.1200/jco.2008.26.15_suppl.19134

Web Of Science Accession Number

Start Page

• 19134

End Page

• 19134

Volume

• 26

Issue

• 15_suppl

Abstract

UOW Authors

•   Ranson, Marie (external author)

Publication Date

• 2008

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Felip, E., Ranson, M., Cedres, S., Dean, E., De Droogh, E., Brewster, M., . . . Galdermans, D. (2008). A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients. Journal of Clinical Oncology, 26(15_suppl), 19134. doi:10.1200/jco.2008.26.15_suppl.19134

Digital Object Identifier (doi)

• 10.1200/jco.2008.26.15_suppl.19134

Web Of Science Accession Number

Start Page

• 19134

End Page

• 19134

Volume

• 26

Issue

• 15_suppl